HiLung Inc.


Based on our proprietary respiratory cell differentiation and engineering technologies, we at HiLungmass produce airway & alveolar epithelial cells and organoids from human iPSCs (induced pluripotent stem cells), in both 2D and 3D formats, with added complexity as needed, such as macrophages and fibroblasts.  Our very human-relevant cells can be utilized in various ways, from assessment of epithelial entry/uptake and antibody activity in vitro, to generation of viral and respiratory subcellular compounds as vaccine components, using our respiratory cells as organic production beds.  More readily, we offer CRO services assessing therapeutic candidates, for diseases including respiratory infections (e.g., COVID, flu, RSV), pulmonary fibrosis, and cystic fibrosis, and for lung toxicity and pollutant particle screening.  Our organoid's accessibility and additive complexity enable unique and highly reproducible opportunities for granular analysis such as single cell-seq and cytokine profiling.  We also offer underlying alveolar and airway cell plates for customers as ready-to-use, room temperature shipment, in both in ALI (air-liquid interface) and in conventional submerged formats, the latter with high throughput as 96- and 384-well plates – which are particularly useful in respiratory pandemic preparedness context.  We offer novel and human-relevant insights from our unique platform technology, by "Translating human(e) inspiration.